Quintiles Named Preferred Provider in Phase I Market Report

Before you go, we thought you'd like these...
Before you go close icon

Quintiles Named Preferred Provider in Phase I Market Report

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles is the preferred Phase I service provider and most frequently cited as the leading provider for complex studies, according to 119 pharmaceutical and biotechnology professionals surveyed in Industry Standard Research's (ISR) 2013 Phase I Study Trends and Market Outlook Report. This announcement comes on the heels of Quintiles' recognition as the industry leader and highest in service quality in Phase II/III clinical research in a separate ISR report released in May.

"The early clinical development landscape continues to increase in complexity as candidate drug molecules and their biological targets become more complex and Phase I studies move into patient populations," said Oren Cohen, M.D., Senior Vice President of Early Clinical Development at Quintiles. "We are delighted to be recognized as the industry's preferred provider because it reflects our ability to deliver complex studies in an increasing complex environment, working with our customers to develop a pathway that informs go/no-go decisions with a high degree of confidence. Our scientific expertise and integrated offerings help customers increase their probability of making good development decisions."


Survey respondents with responsibility and decision-making authority for Phase I study conduct and outsourcing activities selected Quintiles as the preferred provider among all Clinical Research Organization (CROs). They also ranked Quintiles as the most frequently cited service provider that biopharmaceutical companies turn to for complex studies, with therapeutic expertise, scientific knowledge, access to patient populations, patient/volunteer recruitment strategy, prior positive experience and overall value among the most important attributes for selecting a provider for complex studies.

More information about the ISR report is available at http://www.isrreports.com/product/2013-phase-i-study-trends-and-market-outlook/.

About Quintiles

Quintiles (NYS: Q) is the world's largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.

Click here to subscribe to Mobile Alerts for Quintiles.

anImage


Quintiles
Mari Mansfield, +1-919-998-2639
Media Relations
mari.mansfield@quintiles.com
Mobile: +1-919-259-3298
or
Karl Deonanan, +1-919-998-2789
Investor Relations
InvestorRelations@quintiles.com

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:

The article Quintiles Named Preferred Provider in Phase I Market Report originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners